

Kwok Kin Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633109/publications.pdf>

Version: 2024-02-01

310
papers

52,629
citations

950

115
h-index

1496

219
g-index

325
all docs

325
docs citations

325
times ranked

59462
citing authors

#	ARTICLE	IF	CITATIONS
1	A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. <i>Cell</i> , 2010, 141, 69-80.	13.5	2,162
2	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2070-2075.	3.3	1,702
3	Non-small-cell lung cancers: a heterogeneous set of diseases. <i>Nature Reviews Cancer</i> , 2014, 14, 535-546.	12.8	1,375
4	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. <i>Nature Medicine</i> , 2008, 14, 1351-1356.	15.2	1,238
5	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. <i>Science</i> , 2014, 343, 305-309.	6.0	1,196
6	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	5.8	1,163
7	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
8	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. <i>Cancer Discovery</i> , 2013, 3, 1355-1363.	7.7	1,073
9	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
10	A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene. <i>Cell</i> , 2009, 137, 835-848.	13.5	912
11	LKB1 modulates lung cancer differentiation and metastasis. <i>Nature</i> , 2007, 448, 807-810.	13.7	907
12	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009, 462, 1070-1074.	13.7	886
13	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009, 41, 1238-1242.	9.4	862
14	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	7.7	706
15	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	7.7	696
16	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib. <i>Cancer Research</i> , 2007, 67, 11924-11932.	0.4	674
17	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. <i>Nature</i> , 2016, 534, 129-132.	13.7	637
18	The dTAG system for immediate and target-specific protein degradation. <i>Nature Chemical Biology</i> , 2018, 14, 431-441.	3.9	629

#	ARTICLE	IF	CITATIONS
19	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. <i>Nature Medicine</i> , 2010, 16, 219-223.	15.2	613
20	A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. <i>Cancer Research</i> , 2011, 71, 6051-6060.	0.4	560
21	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
22	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. <i>Cell</i> , 2014, 159, 1126-1139.	13.5	498
23	mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. <i>Nature</i> , 2018, 561, 556-560.	13.7	498
24	Targeting the PI3K signaling pathway in cancer. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 87-90.	1.5	494
25	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 78-89.	7.7	455
26	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.4	451
27	Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging. <i>Biological Psychiatry</i> , 2006, 60, 432-435.	0.7	444
28	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
29	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012, 483, 613-617.	13.7	430
30	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006, 9, 485-495.	7.7	427
31	Repression of c-myc Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation. <i>Science</i> , 1997, 276, 596-599.	6.0	402
32	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	6.6	400
33	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	7.7	392
34	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.	7.7	376
35	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014, 513, 110-114.	13.7	367
36	Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. <i>Nature</i> , 2003, 421, 643-648.	13.7	365

#	ARTICLE	IF	CITATIONS
37	High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9625-9630.	3.3	360
38	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	7.7	356
39	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
40	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nature Medicine, 2018, 24, 638-646.	15.2	351
41	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 2013, 23, 121-128.	7.7	343
42	Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. Cancer Cell, 2014, 25, 590-604.	7.7	332
43	Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8713-8717.	3.3	329
44	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature, 2019, 566, 403-406.	13.7	326
45	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clinical Cancer Research, 2018, 24, 4437-4443.	3.2	321
46	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine, 2006, 12, 852-855.	15.2	313
47	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 2009, 459, 1085-1090.	13.7	311
48	Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nature Genetics, 2000, 26, 85-88.	9.4	297
49	Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19503-19508.	3.3	286
50	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. Journal of Clinical Investigation, 2013, 123, 2921-2934.	3.9	283
51	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell, 2020, 37, 104-122.e12.	7.7	267
52	Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 934-947.	7.7	255
53	A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nature Cell Biology, 2014, 16, 108-117.	4.6	252
54	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18351-18356.	3.3	251

#	ARTICLE	IF	CITATIONS
55	An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 7096-7101.	0.4	250
56	An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. <i>Cancer Research</i> , 2010, 70, 2485-2494.	0.4	250
57	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	15.2	250
58	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7817-7822.	3.3	248
59	LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. <i>Nature</i> , 2016, 539, 390-395.	13.7	248
60	Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. <i>Cancer Discovery</i> , 2018, 8, 276-287.	7.7	248
61	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of <i>ERBB2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14476-14481.	3.3	246
62	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014, 20, 1027-1034.	15.2	243
63	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017, 23, 1063-1071.	15.2	240
64	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. <i>Nature Medicine</i> , 2011, 17, 875-882.	15.2	238
65	Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors. <i>Cancer Cell</i> , 2011, 20, 400-413.	7.7	231
66	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009, 119, 1727-1740.	3.9	230
67	Somatic LKB1 Mutations Promote Cervical Cancer Progression. <i>PLoS ONE</i> , 2009, 4, e5137.	1.1	229
68	Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2012, 104, 476-487.	3.0	228
69	PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. <i>Nature Immunology</i> , 2020, 21, 442-454.	7.0	228
70	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to Topoll inhibitors. <i>Nature</i> , 2015, 520, 239-242.	13.7	223
71	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019, 9, 926-943.	7.7	220
72	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. <i>Cancer Cell</i> , 2010, 17, 547-559.	7.7	215

#	ARTICLE	IF	CITATIONS
73	Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. <i>Cancer Cell</i> , 2007, 12, 81-93.	7.7	212
74	A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3068-3077.	3.2	212
75	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	15.2	212
76	Intron retention is a source of neopeptides in cancer. <i>Nature Biotechnology</i> , 2018, 36, 1056-1058.	9.4	212
77	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i> -Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015, 5, 960-971.	7.7	211
78	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. <i>Molecular Cell</i> , 2015, 60, 571-583.	4.5	202
79	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.	15.2	196
80	Characterization of the cell of origin for small cell lung cancer. <i>Cell Cycle</i> , 2011, 10, 2806-2815.	1.3	183
81	Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by <i>EML4-ALK</i> Fusion Oncogene. <i>Cancer Research</i> , 2010, 70, 9827-9836.	0.4	181
82	Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. <i>EMBO Journal</i> , 2014, 33, 468-481.	3.5	181
83	Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6183-6192.	3.2	179
84	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. <i>Cancer Research</i> , 2013, 73, 834-843.	0.4	171
85	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. <i>Cancer Research</i> , 2013, 73, 2574-2586.	0.4	170
86	Inhibition of <i>KRAS</i> -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. <i>Cancer Discovery</i> , 2014, 4, 452-465.	7.7	169
87	HER2 ^{YVMA} drives rapid development of adenocarcinoma lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 474-479.	3.3	163
88	LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18892-18897.	3.3	157
89	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	7.7	157
90	Clinical implications of monitoring nivolumab immunokinetics in non-“small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	2.3	156

#	ARTICLE	IF	CITATIONS
91	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. <i>Cancer Research</i> , 2007, 67, 4933-4939.	0.4	155
92	Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 1758.	5.8	155
93	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 5195-5205.	0.4	153
94	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 371-380.	3.0	153
95	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1268-1279.	0.5	152
96	SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2014, 124, 1636-1645.	3.9	151
97	Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. <i>Cell</i> , 2018, 173, 499-514.e23.	13.5	147
98	Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion. <i>Cancer Research</i> , 2007, 67, 11867-11875.	0.4	146
99	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2013, 8, 322-328.	0.5	145
100	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	7.7	145
101	Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. <i>Journal of Clinical Investigation</i> , 2010, 120, 2528-2536.	3.9	144
102	KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. <i>Journal of Clinical Investigation</i> , 2013, 123, 727-39.	3.9	144
103	Non-Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272. <i>Cancer Research</i> , 2006, 66, 6487-6491.	0.4	141
104	Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance. <i>Cancer Research</i> , 2008, 68, 5827-5838.	0.4	141
105	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4973-4985.	3.2	141
106	Lower Airway Dysbiosis Affects Lung Cancer Progression. <i>Cancer Discovery</i> , 2021, 11, 293-307.	7.7	139
107	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 37-54.e9.	7.7	138
108	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	138

#	ARTICLE	IF	CITATIONS
109	Transdifferentiation of lung adenocarcinoma in mice with <i>Lkb1</i> deficiency to squamous cell carcinoma. <i>Nature Communications</i> , 2014, 5, 3261.	5.8	137
110	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Nonâ€“Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	7.7	132
111	HIF1 α and HIF2 α independently activate SRC to promote melanoma metastases. <i>Journal of Clinical Investigation</i> , 2013, 123, 2078-2093.	3.9	132
112	Primary Tumor Genotype Is an Important Determinant in Identification of Lung Cancer Propagating Cells. <i>Cell Stem Cell</i> , 2010, 7, 127-133.	5.2	130
113	<i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2020, 10, 270-287.	7.7	129
114	HIF2 α cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 2160-2170.	3.9	129
115	Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis. <i>Cancer Prevention Research</i> , 2012, 5, 544-552.	0.7	128
116	Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. <i>Journal of Clinical Investigation</i> , 2014, 124, 5411-5423.	3.9	128
117	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 870-879.	7.7	127
118	Synergy of radiotherapy and PD-1 blockade in <i>Kras</i> -mutant lung cancer. <i>JCI Insight</i> , 2016, 1, e87415.	2.3	125
119	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018, 34, 69-84.e14.	7.7	123
120	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 396-404.	3.2	121
121	Small-molecule targeting of brachyury transcription factor addiction in chordoma. <i>Nature Medicine</i> , 2019, 25, 292-300.	15.2	120
122	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	0.5	119
123	LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. <i>Cancer Cell</i> , 2015, 27, 698-711.	7.7	118
124	LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma. <i>Cancer Cell</i> , 2012, 21, 751-764.	7.7	116
125	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8699-8704.	3.3	114
126	Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Nonâ€“Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1672-1687.	7.7	112

#	ARTICLE	IF	CITATIONS
127	<i>Lkb1</i> inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 181-193.	1.2	108
128	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer. <i>Cancer Research</i> , 2013, 73, 6289-6298.	0.4	108
129	Intratumoral Heterogeneity in <i>EGFR</i> -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015, 75, 4372-4383.	0.4	108
130	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1006-1021.	7.7	108
131	Lysine-specific Demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) Pathway Regulates Cell Cycle Progression and Senescence in Primary Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 33061-33069.	1.6	106
132	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1457-1471.	1.6	105
133	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2014, 124, 5145-5158.	3.9	105
134	Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. <i>Cell Metabolism</i> , 2020, 31, 339-350.e4.	7.2	103
135	Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET. <i>Cancer Research</i> , 2012, 72, 3302-3311.	0.4	100
136	The Pivotal Role of IKK α in the Development of Spontaneous Lung Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2013, 23, 527-540.	7.7	100
137	Loss of <i>Lkb1</i> Provokes Highly Invasive Endometrial Adenocarcinomas. <i>Cancer Research</i> , 2008, 68, 759-766.	0.4	97
138	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. <i>Cancer Discovery</i> , 2018, 8, 59-73.	7.7	96
139	Development of Selective Covalent Janus Kinase 3 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6589-6606.	2.9	94
140	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. <i>Blood</i> , 2010, 115, 559-569.	0.6	93
141	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
142	Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. <i>Cancer Discovery</i> , 2020, 10, 288-305.	7.7	91
143	BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. <i>Nature</i> , 2019, 572, 676-680.	13.7	89
144	Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. <i>Cancer Research</i> , 2013, 73, 6770-6779.	0.4	87

#	ARTICLE	IF	CITATIONS
145	ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2018, 78, 1044-1057.	0.4	87
146	MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. <i>Nature Communications</i> , 2020, 11, 338.	5.8	87
147	Alu elements mediate MYB gene tandem duplication in human T-ALL. <i>Journal of Experimental Medicine</i> , 2007, 204, 3059-3066.	4.2	85
148	Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. <i>Clinical Cancer Research</i> , 2018, 24, 2594-2604.	3.2	85
149	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , 2016, 76, 1538-1548.	0.4	84
150	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. <i>Cancer Biology and Therapy</i> , 2007, 6, 661-667.	1.5	83
151	A dual role for the immune response in a mouse model of inflammation-associated lung cancer. <i>Journal of Clinical Investigation</i> , 2011, 121, 2436-2446.	3.9	82
152	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017, 8, 14922.	5.8	80
153	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1234-1245.	1.6	80
154	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016, 4, 520-530.	1.6	79
155	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 975-985.	1.9	79
156	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	3.9	79
157	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3978-E3986.	3.3	78
158	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. <i>Clinical Cancer Research</i> , 2008, 14, 6478-6486.	3.2	77
159	Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10299-10304.	3.3	77
160	β -Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. <i>Cancer Research</i> , 2014, 74, 5891-5902.	0.4	76
161	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019, 10, 1296.	5.8	73
162	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 503-514.	5.7	72

#	ARTICLE	IF	CITATIONS
163	New cast for a new era: preclinical cancer drug development revisited. <i>Journal of Clinical Investigation</i> , 2013, 123, 3639-3645.	3.9	72
164	Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. <i>Cancer Research</i> , 2010, 70, 4709-4718.	0.4	70
165	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014, 28, 479-490.	2.7	70
166	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. <i>Cancer Research</i> , 2014, 74, 3146-3156.	0.4	69
167	Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 24-32.	1.1	67
168	JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. <i>Journal of Clinical Investigation</i> , 2018, 128, 789-804.	3.9	66
169	DNA-Dependent Protein Kinase Catalytic Subunit Is Not Required for Dysfunctional Telomere Fusion and Checkpoint Response in the Telomerase-Deficient Mouse. <i>Molecular and Cellular Biology</i> , 2007, 27, 2253-2265.	1.1	65
170	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , 2019, 33, 1718-1738.	2.7	65
171	Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. <i>Frontiers in Oncology</i> , 2013, 3, 86.	1.3	64
172	Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. <i>Lung Cancer</i> , 2014, 86, 255-261.	0.9	64
173	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	1.6	62
174	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	0.5	62
175	Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β 1. <i>Journal of Clinical Investigation</i> , 2019, 129, 972-987.	3.9	62
176	Respiratory Failure Due to Differentiation Arrest and Expansion of Alveolar Cells following Lung-Specific Loss of the Transcription Factor C/EBP β in Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 1109-1123.	1.1	61
177	Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16345-16350.	3.3	61
178	Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5423-5434.	3.2	60
179	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	1.6	60
180	Inflammatory cytokines in major depressive disorder: A case-control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 23-31.	1.3	60

#	ARTICLE	IF	CITATIONS
181	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cell Reports</i> , 2019, 28, 512-525.e6.	2.9	59
182	Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. <i>Cell Chemical Biology</i> , 2018, 25, 135-142.e5.	2.5	58
183	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	7.7	58
184	Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. <i>Clinical Cancer Research</i> , 2014, 20, 1204-1211.	3.2	57
185	Targeting PKC δ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Cell</i> , 2018, 34, 954-969.e4.	7.7	56
186	Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. <i>Cancer Cell</i> , 2018, 34, 439-452.e6.	7.7	55
187	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 13897.	5.8	54
188	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , 2014, 5, 8893-8905.	0.8	54
189	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 407-420.	2.0	53
190	Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. <i>JCI Insight</i> , 2018, 3, .	2.3	52
191	Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by <i>DDR2</i> Gatekeeper Mutation and <i>NF1</i> Loss. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 475-482.	1.9	51
192	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , 2015, 29, 27-37.	3.3	51
193	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019, 27, 806-819.e5.	2.9	51
194	RMRP Is a Non-Coding RNA Essential for Early Murine Development. <i>PLoS ONE</i> , 2011, 6, e26270.	1.1	49
195	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4854-4864.	3.2	49
196	HKI-272 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4593s-4596s.	3.2	47
197	Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. <i>Carcinogenesis</i> , 2008, 29, 747-753.	1.3	47
198	TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. <i>Nucleic Acids Research</i> , 1995, 23, 3865-3871.	6.5	46

#	ARTICLE	IF	CITATIONS
199	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1582-1590.	0.3	46
200	Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries. <i>PLoS Genetics</i> , 2017, 13, e1006938.	1.5	46
201	Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. <i>Psychoneuroendocrinology</i> , 2015, 58, 9-22.	1.3	45
202	Noncanonical agonist PPAR β ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 561-566.	3.3	45
203	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. <i>Journal of Clinical Investigation</i> , 2007, 117, 346-352.	3.9	44
204	Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. <i>Nature Communications</i> , 2014, 5, 5870.	5.8	44
205	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <i>Oncology</i> , 2017, 6, e1338998.	2.1	44
206	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. <i>Cancer Research</i> , 2019, 79, 4439-4452.	0.4	44
207	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. <i>Nature Genetics</i> , 2021, 53, 881-894.	9.4	44
208	Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3. <i>Molecular Cancer Research</i> , 2014, 12, 1055-1066.	1.5	43
209	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 1022-1045.	7.7	43
210	The CRTCL1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by <i>LKB1</i> Loss. <i>Cancer Research</i> , 2012, 72, 6502-6511.	0.4	42
211	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 67, 61-69.	0.8	42
212	Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in <i>KRAS</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 31572-31589.	0.8	42
213	Mouse Models of Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4396s-4402s.	3.2	41
214	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	3.2	41
215	MUC1-C integrates activation of the IFN- β pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. , 2021, 9, e002115.		41
216	Differences underlying EGFR and HER2 oncogene addiction. <i>Cell Cycle</i> , 2010, 9, 851-852.	1.3	39

#	ARTICLE	IF	CITATIONS
217	MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017, 7, 7481.	1.6	38
218	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. <i>Cancer Research</i> , 2018, 78, 3709-3717.	0.4	38
219	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
220	Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. <i>Cancer Prevention Research</i> , 2009, 2, 330-337.	0.7	36
221	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 3884-3896.	0.8	34
222	An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. <i>Cancer Discovery</i> , 2021, 11, 696-713.	7.7	34
223	A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. <i>Cancer Biology and Therapy</i> , 2013, 14, 853-859.	1.5	33
224	De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. <i>FASEB Journal</i> , 2018, 32, 7018-7027.	0.2	33
225	EGFR Targeted Therapy: View from Biological Standpoint. <i>Cell Cycle</i> , 2006, 5, 2072-2076.	1.3	32
226	Prospective association between major depressive disorder and leukocyte telomere length over two years. <i>Psychoneuroendocrinology</i> , 2018, 90, 157-164.	1.3	32
227	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. <i>Cancer Research</i> , 2020, 80, 3841-3854.	0.4	32
228	Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response. <i>Cancer Research</i> , 2012, 72, 5921-5933.	0.4	31
229	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. <i>Cancer Research</i> , 2014, 74, 4676-4684.	0.4	31
230	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. <i>Theranostics</i> , 2017, 7, 67-80.	4.6	31
231	Targeting HER2 Exon 20 Insertion Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. <i>Cancer Research</i> , 2021, 81, 5311-5324.	0.4	31
232	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.4	30
233	NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2382-2389.	1.9	29
234	Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 6993-7005.	3.2	29

#	ARTICLE	IF	CITATIONS
235	Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M. <i>Cell Reports</i> , 2014, 7, 1824-1832.	2.9	28
236	NF- κ B Fans the Flames of Lung Carcinogenesis. <i>Cancer Prevention Research</i> , 2010, 3, 403-405.	0.7	27
237	Use of <i>Ex Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2393-2403.	3.2	27
238	Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. <i>Nature Communications</i> , 2021, 12, 4853.	5.8	27
239	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 130, 612-624.	3.9	27
240	Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2014, 9, 254-258.	0.5	26
241	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	2.6	26
242	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, , .		26
243	Differential Roles of Telomere Attrition in Type I and II Endometrial Carcinogenesis. <i>American Journal of Pathology</i> , 2008, 173, 536-544.	1.9	25
244	Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 5068-5076.	0.4	24
245	Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example. <i>Scientific World Journal</i> , The, 2010, 10, 2003-2018.	0.8	23
246	FBXO4 loss facilitates carcinogen induced papilloma development in mice. <i>Cancer Biology and Therapy</i> , 2015, 16, 750-755.	1.5	23
247	Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e80885.	1.1	23
248	The age of cancer: telomeres, checkpoints, and longevity. <i>Journal of Clinical Investigation</i> , 2003, 111, S9-14.	3.9	22
249	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2008, 60, S10-S18.	0.9	21
250	Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 481-489.	1.9	20
251	Innate $\gamma\delta$ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. <i>Cancer Discovery</i> , 2019, 9, 1288-1305.	7.7	19
252	STOP gene <i>Phactr4</i> is a tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E407-14.	3.3	18

#	ARTICLE	IF	CITATIONS
253	A systems biology pipeline identifies regulatory networks for stem cell engineering. <i>Nature Biotechnology</i> , 2019, 37, 810-818.	9.4	18
254	Targeting the Atf7ip/Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. <i>Cancer Immunology Research</i> , 2021, 9, 1298-1315.	1.6	18
255	Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 3556-3567.	0.4	17
256	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. <i>Oncotarget</i> , 2022, 11, 2029298.	2.1	17
257	Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. <i>Cancer Genetics</i> , 2014, 207, 335-339.	0.2	16
258	Upregulation of IGF1R by Mutant <i>RAS</i> in Leukemia and Potentiation of <i>RAS</i> Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. <i>Clinical Cancer Research</i> , 2014, 20, 5483-5495.	3.2	16
259	Loss of <i>TSC1/TSC2</i> sensitizes immune checkpoint blockade in non-small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabi9533.	4.7	16
260	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017, 88, 15-20.	1.2	15
261	Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 85-94.	1.1	15
262	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. <i>Gut</i> , 2022, 71, 665-675.	6.1	15
263	Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer. <i>Cancer Research</i> , 2012, 72, 1-1.	0.4	15
264	Walking the Telomere Plank Into Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1184-1186.	3.0	14
265	The LKB1 Tumor Suppressor as a Biomarker in Mouse and Human Tissues. <i>PLoS ONE</i> , 2013, 8, e73449.	1.1	14
266	Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 614-628.	5.7	14
267	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. <i>Oncotarget</i> , 2015, 6, 11357-11368.	0.8	13
268	Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy. <i>Advanced Science</i> , 2021, 8, e2101999.	5.6	13
269	Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. <i>Genes and Development</i> , 2016, 30, 2684-2695.	2.7	11
270	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. <i>Oncotarget</i> , 2017, 8, 59008-59022.	0.8	11

#	ARTICLE	IF	CITATIONS
271	The impact of the MYB-NFIB fusion proto-oncogene in vivo. <i>Oncotarget</i> , 2016, 7, 31681-31688.	0.8	11
272	EZH2 Inhibitors: Take It EZy, It Is All About Context. <i>Cancer Discovery</i> , 2019, 9, 472-475.	7.7	10
273	Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis. <i>Scientific Reports</i> , 2017, 7, 10407.	1.6	9
274	Shining a light on metabolic vulnerabilities in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188462.	3.3	9
275	Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. <i>National Science Review</i> , 2021, 8, nwab014.	4.6	9
276	C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. <i>Journal of Thoracic Oncology</i> , 2007, 2, S380.	0.5	8
277	Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. <i>Comparative Medicine</i> , 2008, 58, 276-81.	0.4	8
278	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non- \hat{c} neuroendocrine Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1379-1390.	1.5	8
279	Temporal Dissection of K-rasG12D Mutant In Vitro and In Vivo Using a Regulatable K-rasG12D Mouse Allele. <i>PLoS ONE</i> , 2012, 7, e37308.	1.1	7
280	Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants. <i>Journal of Biological Chemistry</i> , 2013, 288, 16895-16904.	1.6	6
281	CCAAT/Enhancer Binding Protein \hat{I}^2 Is Dispensable for Development of Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0120647.	1.1	6
282	DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. <i>Clinical Cancer Research</i> , 2022, 28, 3824-3835.	3.2	6
283	Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2411-2417.	1.2	5
284	A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer. <i>Biochemical Pharmacology</i> , 2021, 193, 114792.	2.0	4
285	Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors. , 2011, , .		4
286	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2015, 27, 149.	7.7	3
287	A novel in vivo model for studying conditional dual loss of BLIMP \hat{c} 1 and p53 in B \hat{c} cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017, 92, E138-E145.	2.0	3
288	Can mouse models of cancer reliably improve clinical trial outcome?. <i>Clinical Investigation</i> , 2013, 3, 119-130.	0.0	1

#	ARTICLE	IF	CITATIONS
289	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. Journal of Clinical Oncology, 2014, 32, 2589-2589.	0.8	1
290	Abstract 5436: Targeting oncoproteins via disruption of proteostasis: Identification of oncoprotein destabilizing agents using luciferase tagged oncoproteins. , 2015, , .		1
291	Abstract 2595: Efficacy of cetuximab and mutant selective EGFR inhibitor WZ4002 in EGFR T790M and non-T790M models of erlotinib resistant non-small cell lung cancer. , 2015, , .		1
292	Immune profiling of malignant pleural mesothelioma by flow cytometry identifies distinct T-cell activation and exhaustion phenotypes in PD-L1 positive versus PD-L1 negative tumors. Journal of Thoracic Oncology, 2016, 11, S17.	0.5	0
293	Using stem cell biology to design precision medicine for non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S4-S5.	0.5	0
294	Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345.	3.0	0
295	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL.. Blood, 2006, 108, 1408-1408.	0.6	0
296	C6-07: Mutations in the LKB1 tumor suppressor are frequently found in tumors from Caucasian NSCLC patients. Journal of Thoracic Oncology, 2007, 2, S378-S379.	0.5	0
297	Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib. , 2011, , .		0
298	Abstract LB-22: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibition in vitro and in vivo. , 2011, , .		0
299	Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers. , 2011, , .		0
300	Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFR L858R/T790M. , 2011, , .		0
301	Abstract LB-399: Chronic inhibition of mutant EGFR in NSCLC leads to EGFR TKI resistance by TGF-β1 mediated epithelial to mesenchymal transition. , 2011, , .		0
302	Abstract 2016: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibition in vitro and in vivo. , 2012, , .		0
303	Abstract 875: Marked in vivo efficacy of combined BCLXL and MEK inhibition in KRAS mutant cancers revealed by a pooled shRNA-drug screen for genes that are synthetically lethal with MEK inhibitors. , 2012, , .		0
304	Mouse models of cancer “ how to optimize their predictive value in cancer drug development. FASEB Journal, 2013, 27, 1088.17.	0.2	0
305	Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models. , 2013, , .		0
306	Abstract LB-125: Selective inhibition of CDK7 targets MYCN-driven transcriptional amplification in neuroblastoma. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
307	Abstract 4851: Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC. , 2014, , .		0
308	Abstract 1471: Establishment, characterization, and clinical correlation of a platform of ovarian patient-derived xenograft (PDX) models. , 2015, , .		0
309	Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair. , 2015, , .		0
310	Abstract 1355: Functional inactivation of LKB1 increases the production of pro-inflammatory cytokines and governs response to immune modulation. , 2015, , .		0